Ahead of Tuesday’s trading session, Stock-Callers.com puts focus on four major players in the Drug Manufacturers space; Pharma majors Sanofi SA, Impax Laboratories Inc., Heron Therapeutics Inc. , and GW Pharmaceuticals PLC .
These companies operate in the Healthcare sector, which trended lower on Monday, March 13, 2017, with the NYSE Health Care Index dropping about 0.1%, while shares of health care companies in the S&P 500 also were down over 0.1% as a group.
Stock-Callers noted that, on Monday, shares in Paris, France headquartered Sanofi recorded a trading volume of 775,188 shares. The stock ended at $43.84, declining 0.16% from the last trading session. Sanofi’s shares have gained 2.67% in the last one month, 10.23% over the previous three months, and 8.41% on an YTD basis. The report further noted The stock is trading above its 50-day and 200-day moving averages by 5.37% and 8.83%, respectively. Furthermore, shares of Sanofi, which researches, develops, manufactures, and markets therapeutic solutions, have a Relative Strength Index (RSI) of 61.85.
Stock-Callers pointed out that Regeneron Pharmaceuticals and Sanofi announced on March 07, 2017, that new Phase-3 data from the Praluent (alirocumab) Injection clinical trial program will be presented at the American College of Cardiology Scientific Sessions (ACC.), March 17-19, 2017 in Washington, D.C. Key data include presentations on the effects of Praluent across several patient subsets such as diabetes, heterozygous familial hypercholesterolemia (HeFH), and atherosclerotic cardiovascular disease. On March 9, 2017, research firm Liberum initiated a ‘Hold’ rating on the Sanofi’s stock.
Impax Laboratories, California based company, finished Monday with stocks of 2.26% higher at $9.05 with a total trading volume of 1.55 million shares. The company’s shares are trading below their 50-day moving average by 28.44%. Shares of the company, which develops, manufactures, and markets bioequivalent pharmaceutical products, have an RSI of 32.93. On March 8, 2017, research firm Deutsche Bank upgraded Impax’s stock rating from ‘Hold’ to ‘Buy’, with a target price of $11 per share.
On March 1, 2017, Impax reported that total revenues in Q4 2016 decreased 29.7% to $198.4 million compared to $282.1 million in Q4 2015, due primarily to increased competition and/or lower pricing on generic diclofenac sodium gel 3%, metaxalone, fenofibrate and mixed amphetamine salts ER. On a GAAP basis, the company recorded a per share loss of $3.91 in Q4 2016 compared to income of $0.16 per diluted share in Q4 2015.
At the close of trading on Monday, shares in Redwood City, California headquartered Heron Therapeutics Inc. saw a slight decline of 0.34%, ending the day at $14.65. The stock recorded a trading volume of 594,293 shares. The Company’s shares have advanced 8.52% in the last one month and 11.83% since the start of this year. The stock is trading 8.00% above its 50-day moving average. Moreover, shares of Heron Therapeutics, which develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the US, have an RSI of 55.90, said Stock-Callers.
On February 24, 2017, Heron Therapeutics announced the inclusion of Sustol (granisetron) extended-release injection as part of the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis Version 1.2017. The NCCN has given Sustol a Category 1 recommendation, the highest level category of evidence and consensus, for use in the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving HEC or MEC regimens.
On February 27, 2017, research firm Needham initiated a ‘Buy’ rating on Her0n’s stock, with a target price of $28 per share.
GW Pharmaceuticals PLC’s shares ended the day 1.39% lower at $123.33. A total volume of 405,107 shares was traded, which was above their three months average volume of 362,730 shares. The stock has gained 4.35% over the previous three months and 10.36% on an YTD basis. The Cambridge, UK-based company’s shares are trading 0.84% above their 50-day moving average and 13.12% above their 200-day moving average. Additionally, shares of GW Pharma, which engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant, have an RSI of 44.57.
On March 7, 2017, GW Pharmaceuticals announced the appointment of Scott Giacobello as Chief Financial Officer on 06th March 2017. Related to this appointment, on 6th March 2017 Adam George, GW’s Chief Financial Officer since 2012, became Managing Director – UK, a newly-created executive role with broad leadership responsibilities for UK operations.
Read more at http://stock-callers.com/